Fundraising Fox
Ideaya Biosciences
NASDAQ: IDYASouth San Francisco, US · Founded 2015 · Delaware corporation · 281 employees on LinkedIn · 6 known investors
Find your way into Ideaya Biosciences
97 people in our graph can introduce you to the Ideaya Biosciences team.
Sign up to see every warm intro you have to Ideaya Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ideaya Biosciences team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
Founders & leadership
Board
Investors · 6
How we know: 5AM Ventures's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Canaan Partners's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Nextech Invest's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$111.4M disclosed across 2 rounds · 2016–2018
▶$94MraisedMay 2018 · 23 investors · BiotechnologyRule 506(b)
- Paul A. StoneExecutive Officer
- Yujiro S. HataDirector, Executive Officer
- Jeffrey HagerExecutive Officer
- Edward HuDirector
- Jeffrey SteinDirector
- Terry RosenDirector
- John D. DiekmanDirector
- Brian DanielsDirector
- Timothy ShannonDirector
- Tim SmithExecutive Officer
- Thilo SchroederDirector
- Michael P. DillonExecutive Officer
- Offering amount
- $94M
- Amount sold
- $94M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$17.4MraisedAug 2016 · 10 investors · OtherRule 506(b)
- Paul StoneExecutive Officer
- Yujiro HataExecutive Officer, Director
- Timothy ShannonDirector
- Terry RosenDirector
- Jeffrey SteinDirector
- John DiekmanDirector
- Offering amount
- $46.2M
- Amount sold
- $17.4M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 2
Companies working in the same space as Ideaya Biosciences.
Frequently asked questions
- What does Ideaya Biosciences do?
- IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
- Who are Ideaya Biosciences's investors?
- Ideaya Biosciences's investors include 5AM Ventures, Canaan Partners, GV (Google Ventures), Nextech Invest, Biotechnology Value Fund, WuXi Healthcare Ventures.
- How much funding has Ideaya Biosciences raised?
- Ideaya Biosciences has disclosed $111.4M raised across 2 rounds.
- Where is Ideaya Biosciences headquartered?
- Ideaya Biosciences is headquartered in South San Francisco, US.